The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).
 
Yukiya Narita
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Hirokazu Shoji
No Relationships to Disclose
 
Sadayuki Kawai
No Relationships to Disclose
 
Takuro Mizukami
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Asahi Kasei; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiro Misumi
Employment - Astellas Pharma
 
Yu Yamashige
No Relationships to Disclose
 
Akira Yamashige
No Relationships to Disclose
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)